B-MS keeps Zeposia news coming with ulcerative colitis data

2 June 2020
bristol-myers-squibb-big

Bristol-Myers Squibb (NYSE: BMY) has announced more news on its immunomodulatory drug Zeposia (ozanimod).

The US pharma major launched the drug in the USA on Monday as a treatment for relapsing forms of multiple sclerosis, having gained a European Commission approval in this disease last week.

Zeposia is not just seen as a multiple sclerosis asset by B-MS, however. It is also in development for additional immune-inflammatory indications, including ulcerative colitis and Crohn’s disease.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology